Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Amicus Therapeutics (FOLD) over the last 16 years, with Q3 2025 value amounting to $10.9 million.

  • Amicus Therapeutics' Non Operating Income rose 43365.0% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 20089.04%. This contributed to the annual value of -$9.4 million for FY2024, which is 4057.03% up from last year.
  • As of Q3 2025, Amicus Therapeutics' Non Operating Income stood at $10.9 million, which was up 43365.0% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Non Operating Income ranged from a high of $13.6 million in Q3 2022 and a low of -$18.6 million during Q4 2022
  • Moreover, its 5-year median value for Non Operating Income was $234000.0 (2021), whereas its average is -$610526.3.
  • Over the last 5 years, Amicus Therapeutics' Non Operating Income had its largest YoY gain of 565274.26% in 2022, and its largest YoY loss of 1073023.26% in 2022.
  • Amicus Therapeutics' Non Operating Income (Quarter) stood at -$172000.0 in 2021, then crashed by 10730.23% to -$18.6 million in 2022, then skyrocketed by 84.54% to -$2.9 million in 2023, then soared by 187.01% to $2.5 million in 2024, then soared by 334.61% to $10.9 million in 2025.
  • Its Non Operating Income was $10.9 million in Q3 2025, compared to $1.0 million in Q2 2025 and $550000.0 in Q1 2025.